Femasys Seeks Shareholder Approval for Reverse Stock Split and Major Dilutive Issuances to Avoid Delisting

summarizeSummary

Femasys Inc. is calling a special meeting to vote on a reverse stock split to avoid Nasdaq delisting and to approve the issuance of shares from existing convertible notes and warrants, which could lead to significant shareholder dilution.

check_boxKey Events

• Special Shareholder Meeting Called

  A Special Meeting of Stockholders is scheduled for April 29, 2026, to vote on critical proposals, including a reverse stock split and approval for dilutive share issuances.

• Reverse Stock Split Proposed to Avoid Delisting

  The board seeks approval for a reverse stock split in a range of 1-for-2 to 1-for-25 to regain compliance with Nasdaq's $1.00 minimum bid price rule by the July 13, 2026 deadline. The company explicitly states the split will also facilitate future dilutive equity capital raises.

• Approval Sought for Significant Dilutive Issuances

  Shareholders are asked to approve the issuance of shares upon conversion of senior secured convertible notes and exercise of Series A-1, B-1, C-1 (November 2025) and Series D-1 (March 2026) warrants. This approval is necessary to allow full conversion/exercise if anti-dilution or price adjustment provisions result in an effective price below the Nasdaq Minimum Price, exceeding the 20% issuance cap.

• Insider Participation in Dilutive Securities

  Certain directors and officers participated in the private placements of these convertible notes and warrants, requiring specific shareholder approval for their potential issuances under Nasdaq rules if effective prices fall below the minimum.

auto_awesomeAnalysis

Femasys Inc. is at a critical juncture, seeking shareholder approval for two highly impactful proposals. The proposed reverse stock split, ranging from 1-for-2 to 1-for-25, is a direct response to the company's non-compliance with Nasdaq's $1.00 minimum bid price rule and the threat of delisting. While necessary for continued listing, reverse splits often signal underlying operational challenges and can lead to further share price declines. Critically, the reverse split will also dramatically increase the number of authorized but unissued shares, explicitly stated as a means to facilitate future dilutive capital raises. Concurrently, the company seeks approval to issue a substantial number of shares from existing convertible notes and warrants (including recently issued Series D-1 warrants) beyond Nasdaq's 20% rule, particularly if anti-dilution provisions trigger lower effective prices. The participation of directors and officers in these private placements, requiring specific shareholder approval, adds a layer of concern regarding potential self-interest and the magnitude of future dilution. This filing indicates the company is preparing for significant capital raises that could substantially dilute existing shareholders, making it a high-risk investment.